Showing results (281-290 of 294) with videos related to

Sort By:
Pageof 30
Cytometry. Part B, Clinical Cytometry|October 27, 2016
CD44 as a Potential Screening Marker for Preliminary Differentiation Between Congenital Dyserythropoietic Anemia Type II and Hereditary SpherocytosisB K Singleton, M Ahmed, C A Green, et al.
Bone Marrow Transplantation|September 19, 2006
Phase I/II trial of multicycle high-dose chemotherapy with peripheral blood stem cell support for treatment of advanced ovarian cancerN Frickhofen, W E Berdel, F Opri, et al.
Leukemia|April 15, 2005
Gender aspects in chronic myeloid leukemia: long-term results from randomized studiesU Berger, O Maywald, M Pfirrmann, et al.
Leukemia|October 17, 2003
Marrow fibrosis, indicator of therapy failure in chronic myeloid leukemia - prospective long-term results from a randomized-controlled trialG Buesche, R Hehlmann, H Hecker, et al.
Leukemia|April 1, 1997
Randomized studies with interferon in chronic myelogenous leukemia (CML) and comparative molecular aspects. German CML Study GroupR Hehlmann, A Willer, H Heimpel, et al.
Leukemia|July 31, 2004
Treatment intensity significantly influencing fibrosis in bone marrow independently of the cytogenetic response: meta-analysis of the long-term results from two prospective controlled trials on chronic myeloid leukemiaG Buesche, M Freund, R Hehlmann, et al.
Leukemia|January 9, 2004
A prospective, randomised, phase II study of horse antithymocyte globulin vs rabbit antithymocyte globulin as immune-modulating therapy in patients with low-risk myelodysplastic syndromesM Stadler, U Germing, K-O Kliche, et al.
Leukemia|September 13, 2003
Chronic myeloid leukemia in the elderly: long-term results from randomized trials with interferon alphaU Berger, G Engelich, O Maywald, et al.
Blood|March 21, 1998
Survival with bone marrow transplantation versus hydroxyurea or interferon for chronic myelogenous leukemia. The German CML Study GroupR P Gale, R Hehlmann, M J Zhang, et al.
Blood|November 26, 1999
Interferon-alpha before allogeneic bone marrow transplantation in chronic myelogenous leukemia does not affect outcome adversely, provided it is discontinued at least 90 days before the procedureR Hehlmann, A Hochhaus, H J Kolb, et al.
Pageof 30